Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.57 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | CPA1 | P15085 | 2/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846869 | 0.82 | MME (0.59) | MMEITGB1ITGA4PTPN1FFAR1 | |
| SCHEMBL7608499 | 0.82 | CTRB1 (0.65) | MMECTRB1ECE1 | |
| SCHEMBL7608505 | 0.82 | CTRB1 (0.65) | MMECTRB1ECE1 | |
| SCHEMBL8316621 | 0.78 | ITGB1 (0.55) | MMEITGB1ITGA4PTPN1FFAR1 | |
| SCHEMBL7439103 | 0.76 | MME (0.43) | MMEITGB1ITGA4PTPN1ACE | |
| SCHEMBL8445937 | 0.76 | MME (0.53) | MMEITGB1ITGA4PTPN1FFAR1 | |
| SCHEMBL8312930 | 0.75 | MME (0.54) | MMEITGB1ITGA4PTPN1FFAR1 | |
| SCHEMBL5164419 | 0.74 | SLC7A5 (0.57) | MMEITGB1ITGA4PTPN1FFAR1 | |
| SCHEMBL5164414 | 0.74 | SLC7A5 (0.57) | MMEITGB1ITGA4PTPN1FFAR1 | |
| SCHEMBL8317308 | 0.74 | MME (0.54) | MMEITGB1ITGA4PTPN1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020161030-A1 | Sulpur derivatives containing a retroamide bond as inhibitors of endothelin-converting enzymes | HOECHST MARION ROUSSEL | 2002-10-31 | — | — | US | disclosed |
| US-6420341-B1 | TREATING VASOCONSTRICTOR AND HYPERTENSION EFFECTS IN WARM-BLOODED ANIMALS | AVENTIS PHARMA S.A. (FR) | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161030-A1 | Sulpur derivatives containing a retroamide bond as inhibitors of endothelin-converting enzymes | EDNRA, ECE1, EDNRB | MME 8/4885ITGB1 3945/4885ITGA4 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.